Germany's BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, its CEO Ugur Sahin said in an interview during the Reuters Next conference, adding that despite the mutation shots should continue to protect people against severe disease.

#Omicron #COVID #BioNTech #ReutersNext #News #Reuters

Subscribe: http://smarturl.it/reuterssubscribe

Reuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is unparalleled.

Get the latest news on: http://reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on Twitter: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en